




The relative strengths and weaknesses of Blueprint Medicines Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Blueprint Medicines Corp compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 123% points. The greatest weakness of Blueprint Medicines Corp is the variable Research and Development, reducing the Economic Capital Ratio by 11% points.

The company's Economic Capital Ratio, given in the ranking table, is 369%, being 106% points above the market average of 263%.

Input Variable	Value in 1000 USD
Assets, Current	170,416
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	18,640
Liabilities, Non-Current	0
Other Assets	1,821
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-1,125
Other Revenues	11,400
Property and Equipment	6,661
Research and Development	48,588
Selling, General and Administrative Expense	14,456

Output Variable	Value in 1000 USD
Assets	178,898
Liabilities	18,640
Expenses	63,044
Revenues	11,400
Stockholders Equity	160,258
Net Income	-52,769
Comprehensive Net Income	-52,769
BaseVar	136,554
ECR before Limited Liability	300%
Economic Capital Ratio	369%